Google
CBIO — CRESCENT BIOPHARMA, INC. (Healthcare >> Biotechnology)
CBIO FAQ
What is CBIO's ROE?
CRESCENT BIOPHARMA, INC. reports a Return on Equity (ROE) of -88.16%.
What is CBIO's dividend yield?
CRESCENT BIOPHARMA, INC. offers a dividend yield of 0.00%.
What is CBIO's Deepscope Quality Score?
Deepscope rates CBIO's overall financial quality at 8 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CBIO?
Deepscope's AI Timing Score for CBIO is 67 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CBIO belong to?
CRESCENT BIOPHARMA, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 18.00
Price
-0.45
(-2.44%)
Day Change
|
|
|---|
CBIO, the overall quality is not good ( Quality = 8) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 18.00 |
| PBV / Sector |
2.70 / 4.63
|
| Earning Per Share | -5.88 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
5.52 M
GREAT
|
| Average 1W Daily Value |
4.95 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
52% |
| Return to Investors |
|
41% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:28 |
| Symbol | CBIO |
| Name | CRESCENT BIOPHARMA, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 27.57 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 495.80 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 300 Fifth Avenue, Waltham, MA, United States, 02451
Phone: 617 460 5595
Website: https://crescentbiopharma.com
Employees: 55
Sector: Healthcare >> Biotechnology
Description: Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
